{"id":"pf-07850327-arv-471-vepdegestrant","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"Vepoloxamer","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07850327","action":"Monitor","effect":"Increased risk of hypercalcemia"},{"drug":"ARV-471","action":"Monitor","effect":"Increased risk of hypercalcemia"}],"commonSideEffects":[],"contraindications":["Participants with significant concomitant illness","Active brain metastases","Inadequate liver, kidney and bone marrow function","prior chemotherapy for advanced/metastatic disease","other investigational agents (including novel endocrine therapy any SERDs, SERCAs, CERANs) for any setting","ARV-471, fulvestrant, elacestrant, mTOR, PI3K, AKT pathway inhibitors, PARP inhibitor for any setting","Prior treatment with: Participants with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the"],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07850327-arv-471-vepdegestrant","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:56:13.011586+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:56:19.616950+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:56:13.031410+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07850327-arv-471-vepdegestrant","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:56:20.361574+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5095210/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:21.526518+00:00"}},"allNames":"pf-07850327, arv-471, vepdegestrant","offLabel":[],"timeline":[{"date":"2021-06-01","type":"Clinical Trial","milestone":"Phase 1/2 trial initiation for vepdegestrant","regulator":"FDA"},{"date":"2022-03-01","type":"Clinical Trial","milestone":"Phase 2 trial initiation for ARV-471","regulator":"FDA"},{"date":"2023-01-01","type":"Clinical Trial","milestone":"Phase 3 trial initiation for PF-07850327","regulator":"FDA"}],"_dailymed":null,"aiSummary":"PF-07850327, ARV-471, and vepdegestrant are investigational drugs being developed by Pfizer Inc. These compounds are in various stages of clinical development for the treatment of hormone receptor-positive breast cancer. PF-07850327 is a selective estrogen receptor degrader (SERD), while ARV-471 is a next-generation SERD, and vepdegestrant is an oral selective estrogen receptor covalent antagonist (SERCA). The drugs aim to improve upon existing treatments by offering better efficacy and safety profiles. Clinical trials are ongoing to evaluate their safety and effectiveness.","brandName":"PF-07850327, ARV-471, vepdegestrant","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Estrogen Receptor (ER)","novelty":"Next-generation SERDs and SERCAs with improved potency and safety profiles compared to existing treatments","modality":"Small Molecule","drugClass":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","explanation":"","oneSentence":"","technicalDetail":"PF-07850327 and ARV-471 are selective estrogen receptor degraders (SERDs) that bind to the ER and promote its degradation, while vepdegestrant is a selective estrogen receptor covalent antagonist (SERCA) that forms a covalent bond with the ER, leading to its inactivation."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:46.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","launchDate":null,"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Hormone receptor-positive breast cancer patients","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07850327-arv-471-vepdegestrant","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07850327-arv-471-vepdegestrant","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:23.398615+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":["Elacestrant (Radius Health)","Camizestrant (AstraZeneca)","Giredestrant (Amgen)"],"genericName":"pf-07850327-arv-471-vepdegestrant","indications":{"approved":[{"name":"Non-small cell lung cancer","regulator":"FDA"},{"name":"Breast cancer","regulator":"FDA"},{"name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer","regulator":"FDA"},{"name":"Hormone receptor-positive breast cancer","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation and hormone receptor-positive","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation and HER2-negative","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, and HER2-negative","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, and ESR1 mutation","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, and ESR1 mutation and/or TP53 mutation","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, and/or TP53 mutation","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, and/or CDK4/6 inhibitor resistance","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, and/or prior endocrine therapy","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, and/or prior chemotherapy","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, and/or prior radiotherapy","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, and/or prior surgery","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, and/or prior hormone therapy","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, and/or prior targeted therapy","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, and/or prior immunotherapy","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, and/or prior chemotherapy with a taxane","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, and/or prior chemotherapy with a platinum agent","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, and/or prior chemotherapy with a microtubule inhibitor","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, and/or prior chemotherapy with a PARP inhibitor","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, and/or prior chemotherapy with a mTOR inhibitor","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, and/or prior chemotherapy with a HER2-targeted therapy","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, and/or prior chemotherapy with a PIK3CA-targeted therapy","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, and/or prior chemotherapy with a hormone receptor antagonist","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, and/or prior chemotherapy with a hormone receptor agonist","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, and/or prior chemotherapy with a selective estrogen receptor degrader","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, and/or prior chemotherapy with a selective estrogen receptor modulator","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, and/or prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor","regulator":"FDA"},{"name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor and/or a PIK3CA inhibitor","regulator":"FDA"}],"offLabel":[],"pipeline":["Hormone Receptor-Positive Breast Cancer"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05654623","phase":"PHASE3","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-03","conditions":"Advanced Breast Cancer","enrollment":624},{"nctId":"NCT05573555","phase":"PHASE1, PHASE2","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-01","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT06206837","phase":"PHASE1, PHASE2","title":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-02-19","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT05909397","phase":"PHASE3","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-08-09","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT05548127","phase":"PHASE1, PHASE2","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-02-23","conditions":"Breast Cancer","enrollment":37},{"nctId":"NCT07231991","phase":"PHASE1","title":"A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2025-11-04","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT06125522","phase":"PHASE1, PHASE2","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-10","conditions":"Breast Cancer","enrollment":11},{"nctId":"NCT05549505","phase":"PHASE2","title":"A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery","status":"COMPLETED","sponsor":"Arvinas Inc.","startDate":"2023-02-15","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT04606446","phase":"PHASE1","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2020-11-16","conditions":"Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":320},{"nctId":"NCT06911788","phase":"PHASE1","title":"A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-03","conditions":"Healthy Participants","enrollment":10},{"nctId":"NCT06645938","phase":"PHASE1","title":"A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-10-16","conditions":"Healthy","enrollment":12},{"nctId":"NCT05732428","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-20","conditions":"Breast Cancer","enrollment":9},{"nctId":"NCT06256510","phase":"PHASE1","title":"A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Healthy Participants","enrollment":15},{"nctId":"NCT05463952","phase":"PHASE1","title":"A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-16","conditions":"Breast Neoplasms","enrollment":6},{"nctId":"NCT06347861","phase":"PHASE1","title":"A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-04-02","conditions":"Healthy","enrollment":52},{"nctId":"NCT05538312","phase":"PHASE1","title":"A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-23","conditions":"Healthy","enrollment":12},{"nctId":"NCT06275841","phase":"PHASE1","title":"A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-02-23","conditions":"Healthy","enrollment":12},{"nctId":"NCT06005688","phase":"PHASE1","title":"A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-08-18","conditions":"Healthy Participants","enrollment":12}],"_emaApprovals":[{"date":"","name":"PF-07850327, ARV-471, vepdegestrant","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5095210","moleculeType":"Small molecule","molecularWeight":"723.92"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5095210"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:23.398615+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}